"Recent progress includes:
-- Abstracts detailing our findings in the first two clinical cohorts
have been accepted for presentation at ASCO. These studies examine
correlations between eTag assay measurements and clinical outcomes.
-- An abstract describing patterns of homo- and hetero-dimers in cell
lines with resistance to Herceptin has been accepted for presentation
at ASCO.
-- Manuscripts describing the eTag methodology and initial results in two
clinical cohorts of patients with metastatic breast cancer are in preparation and nearing submission for publication."
I believe many many people are underestimating the significance of these results.
The company has stated that they believe they have the only effective method to measure homo-dimers in a market that is expected to (according to the company) generate testing revenues of $500M on the low side and $1B on the high side.
If/when eTag hits the market it could mean 10x the revenue that HIV testing will bring in to MGRM (assuming that MGRM captures the same % of the market for Cancer testing as they will with HIV testing) In my opinion that is not a hard assumption to make.
Like I said before this company is well worth a look to anyone with an above average attention span and a better than average ability to realize the meaning of what he/she is reading.
I believe the analysts covering this stock with their $2.50 & $3 price targets are lazy(attentiion span)and have not done their homework;it's just not sinking in with them.
Good Luck!
$11.82 (04/29/07)
